Several small molecules, miRNAs, and proteins have been studied as inhibitors of SREBP1 activity in various cancers, which can be repurposed for breast cancer risk reduction, provided that they exhibit sufficient bioavailability and efficacy in the breast. This evidence concerns the gene SREBF1 and breast carcinoma.